K. Steffy

发表

Transdominant inhibition of wild-type human immunodeficiency virus type 2 replication by an envelope deletion mutant

K. Steffy, F. Wong-Staal, 1993, Journal of virology.

F Wong-Staal an envelope deletion mutant . immunodeficiency virus type 2 replication by Transdominant inhibition of wild-type human

K. Steffy, 2022 .

In Vitro Characterization of A-315675, a Highly Potent Inhibitor of A and B Strain Influenza Virus Neuraminidases and Influenza Virus Replication

F. Hayden, L. Gubareva, A. Molla, 2002, Antimicrobial Agents and Chemotherapy.

In Vitro Selection and Characterization of Influenza A (A/N9) Virus Variants Resistant to a Novel Neuraminidase Inhibitor, A-315675

V. Stoll, A. Molla, D. Kempf, 2002, Journal of Virology.

Role of the fusogenic peptide sequence in syncytium induction and infectivity of human immunodeficiency virus type 2

K. Steffy, F. Wong-Staal, D. Looney, 1992, Journal of Virology.

Initial characterization of autoprocessing and active-center mutants of CMV proteinase

T. Holzman, K. Steffy, F. Lindh, 1996, Journal of protein chemistry.

Nucleotide sequence of the herpes simplex virus type 2 gene encoding the protease and capsid protein ICP35.

K. Steffy, C. M. Chen, S. Schoen, 1995, The Journal of general virology.

Syntheses of novel myxopyronin B analogs as potential inhibitors of bacterial RNA polymerase.

S. Webber, Amit M. Shah, R. Showalter, 2007, Bioorganic & medicinal chemistry letters.

A diketopiperazine dimer from a marine-derived isolate of Aspergillus niger.

Rupal A Patel, K. Steffy, Natalie N. M. Nguyen, 2004, Journal of natural products.

90 PRECLINICAL STUDIES OF ANA598 COMBINED WITH OTHER ANTI-HCV AGENTS DEMONSTRATE POTENTIAL OF COMBINATION TREATMENT

P. A. Thompson, Rupal A Patel, K. Steffy, 2009 .

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

T. Berg, K. Steffy, S. Fletcher, 2005, Hepatology.

[415] THE ACTIVE METABOLITE OF LB80380/ANA380, A NOVEL NUCLEOTIDE ANALOG, EXHIBITS ACTIVITY IN VITRO AGAINST MULTIPLE CLINICALLY RELEVANT HEPATITIS B VIRUS MUTANTS

K. Steffy, S. Locarnini, T. Shaw, 2007 .

Genetic regulation of human immunodeficiency virus.

K. Steffy, F. Wong-Staal, F. Wong-Staal, 1991, Microbiological reviews.

Genetic regulation of human immunodeficiency virus

K. Steffy, F. Wong-Staal, 1991 .

A minimally replicative HIV-2 live-virus vaccine protects M. nemestrina from disease after HIV-2(287) challenge.

S. Kent, P. Greenberg, K. Steffy, 1998, Virology.

Mutational analysis of two herpes simplex virus type 1 late promoters

K. Steffy, J. Weir, 1991, Journal of virology.

Upstream promoter elements of the herpes simplex virus type 1 glycoprotein H gene

K. Steffy, J. Weir, 1991, Journal of virology.

Discovery of ANA975: An Oral Prodrug of the TLR-7 Agonist Isatoribine

S. Webber, L. Kirkovsky, K. Steffy, 2007, Nucleosides, nucleotides & nucleic acids.

Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients

B. Walker, S. Akira, J. Kaldor, 2011 .

Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors.

Vincent S Stoll, A. C. Krueger, V. Stoll, 2005, Journal of medicinal chemistry.

Design and characterization of an engineered gp41 protein from human immunodeficiency virus-1 as a tool for drug discovery

Kevin Harris, Kent D. Stewart, Kevin Steffy, 2007, J. Comput. Aided Mol. Des..